

A stylized illustration of a human lung in shades of blue and white. A magnifying glass with a black handle is positioned over the lower part of the lung, focusing on a detailed view of the bronchial tree. The background is white with scattered blue circles of various sizes.

GO₂ FOUNDATION
FOR LUNG CANCER

THE

Magnifying LeNS

LEARNING
NEW SCIENCE
QUARTERLY

APRIL 2022

Considering Caregivers: The Lung Cancer Registry's Newest Initiative



Caregivers often help people with lung cancer learn about their disease, perform daily tasks and manage the complex emotional struggles that start at diagnosis. For the caregiver, however, this adds to their own personal stressors—and we want to hear about it. Read more about the groundbreaking survey, and how we think it will make a global impact.

[READ MORE](#)

Small Cell Lung Cancer Transformation: What Is It and How do We Treat it?



People with lung cancer receiving treatment may encounter acquired drug resistance—a reduction in treatment effectiveness over time. This may also lead to transformations, including small cell lung cancer transformation (tSCLC). Read our latest blog to learn more about why tSCLC is a key area of focus for GO2 Foundation and what research is being done to improve outcomes.

[READ MORE](#)

New Screening Guidelines: How They Affect You and What You Need to Know



Lung cancer screening using low dose computed tomography is currently the only proven method to find lung cancer at an early stage. This is critical because lung cancer is more easily treated in the early stages and early detection has led to significantly reduced lung cancer deaths. Recently, the Centers for Medicare and Medicaid Services put out new recommendations making screening more accessible. We're breaking down what you need to know about their decisions in our latest blog.

[READ MORE](#)

Immune Checkpoint Inhibitor Resistance: What to Do Next?



Immunotherapy, a type of treatment that helps the body's own immune system fight cancer, is often discussed as a first line of treatment for people with metastatic non-small cell lung cancer without an actionable biomarker, like EGFR or ALK. Immunotherapy has been proven to provide better outcomes for most of this patient population, though treatment resistance can reduce effectiveness. So, what can be offered to people who develop resistance to the drugs used in immunotherapy, specifically immune checkpoint inhibitors? Read our latest blog to find out.

[READ MORE](#)

Diagnosed with lung cancer before age 50?
Help researchers crack the code!

**Sign up for the Epidemiology of Young
Lung Cancer study!**

About Us

Founded by patients and survivors, GO2 Foundation for Lung Cancer transforms survivorship as the world's leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.

DONATE TODAY!

Contact Us

Email: info@go2foundation.org | HelpLine: 1-800-298-2436 (9-5 EDT)

Washington, DC

Phone: 202-463-2080

San Francisco Bay Area

Phone: 650-598-2857

THANK YOU TO OUR SPONSORS

Genentech
A Member of the Roche Group

REGENERON

sanofi